⌕
Xenon Pharmaceuticals · XENE · Nasdaq
Tenet 44 · Weak
Compare
$38.60−1.67%Market openTenet 44 · Weak
$38.60−0.66 (−1.67%)
Market open · 15-min delayed · as of 10:45 AM ET· Nasdaq · USD

Xenon Pharmaceuticals (XENE) Stock

Xenon Pharmaceuticals (XENE) has a Tenet Score of 44 of 100 against 340 Healthcare peers, as of Nov 16, 2026.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

34 figures withheld by our checks. Each blank figure names its reason.

Key stats

Market cap
$3.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
33.38 – 72.66
low → high · as of close, Nov 16, 2026
Tenet Score
44/100
Weak · 340 Healthcare peers

Industry: Drugs

Xenon Pharmaceuticals Inc scores 44/100. Weak. Strongest on financial health, growth is the soft spot versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
44/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
61
Quality
21
Health
93
Growth
2

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityFHealthAGrowthFMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
3.4×
Sep 30, 2026 balance sheet
P/S
—
Not reported in the company's filings for this period.
ROE
−50%
TTM through Sep 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
Not meaningful: revenue is too small to measure a margin against.
Current ratio
21.19
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Pha…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 66 US ETFs · top wrappers by weightSee all ETFs holding XENE →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Xenon Pharmaceuticals in?

Xenon Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Xenon Pharmaceuticals' Tenet Score?

Xenon Pharmaceuticals' Tenet Score is 44 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.